Current Hematologic Malignancy Reports最新文献_第10页

Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses. 急性淋巴母细胞白血病和急性淋巴母细胞淋巴瘤:相同的疾病谱系但两种不同的诊断。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-08-21 DOI: 10.1007/s11899-021-00648-y

Kathryn A F Kline, Michael E Kallen, Vu H Duong, Jennie Y Law

{"title":"Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses.","authors":"Kathryn A F Kline, Michael E Kallen, Vu H Duong, Jennie Y Law","doi":"10.1007/s11899-021-00648-y","DOIUrl":"https://doi.org/10.1007/s11899-021-00648-y","url":null,"abstract":"Purpose of review: Rare malignancies developing from lymphocyte precursor cells, lymphoblastic leukemia (LBL), and acute lymphoblastic lymphoma (ALL) have historically been viewed as different manifestations of the same disease process. This review examines data on their epidemiology, genetics, clinical presentation, and response to treatment while highlighting areas of similarity and divergence between these two clinical entities.Recent findings: Pediatric-type ALL chemotherapy regimens, compared to both lymphoma-type chemotherapy and adult-type ALL regimens, have led to improved outcomes for children, adolescents, and young adults with ALL. BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) have improved outcomes in Philadelphia chromosome-positive (Ph +) ALL and in rare cases of Ph + LBL. Newer therapies including blinatumomab, inotuzumab, CAR-T therapy, and nelarabine have improved outcomes in selected cases of ALL and have an emerging role in the management of LBL. Better understanding of ALL and LBL biology allows for the development of therapies that target immunophenotypic or genetic features found in subsets of both diseases. Novel therapies are leading to improved outcomes in Ph + and relapsed and refractory disease.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"384-393"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11899-021-00648-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39331064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse. 利用语音平台提升基于twitter的期刊俱乐部讨论:#HemepathJC与Clubhouse会面。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-09-29 DOI: 10.1007/s11899-021-00644-2

Aadil Ahmed, Kamran M Mirza, Sanam Loghavi

引用次数: 3

Avapritinib in the Treatment of Systemic Mastocytosis: an Update. 阿伐替尼治疗系统性肥大细胞增多症的最新进展。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-09-27 DOI: 10.1007/s11899-021-00650-4

Samantha Below, Laura C Michaelis

{"title":"Avapritinib in the Treatment of Systemic Mastocytosis: an Update.","authors":"Samantha Below, Laura C Michaelis","doi":"10.1007/s11899-021-00650-4","DOIUrl":"https://doi.org/10.1007/s11899-021-00650-4","url":null,"abstract":"Purpose of review: Patients with systemic mastocytosis, a dangerous and rare myeloid neoplasm, have long had few therapies available to them and, historically, rarely achieved from significant disease control. However, research and translational developments over the last decade have led to promising new options for disease management. In this review, we briefly outline the history of treatment for systemic mastocytosis and subsequently focus on the clinical development and potential applications of avapritinib (previously known as BLU-285), a potent and selective oral inhibitor of the tyrosine kinase most commonly mutated in this condition.Recent findings: Phase I data and recent phase II data have demonstrated both safety and efficacy of this agent used as monotherapy, even in patients who have progressed on other targeted therapy. Studies to date have focused on patients with the most aggressive disease, but new trials in indolent mastocytosis are accruing currently. Over the next several years, one may anticipate finalized, peer-reviewed, and formally published data for this agent in both advanced systemic and indolent mastocytosis. Evidence from these early studies will also likely highlight where more research is needed.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"464-472"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39464222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Challenges in Chronic Myeloid Leukemia Management in South America. 南美慢性髓性白血病管理的挑战。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-10-15 DOI: 10.1007/s11899-021-00654-0

Katia B Pagnano, Ana Ines Varela, Carolina Pavlovsky, Israel Bendit, Vaneuza A M Funke, Virginia Abello Polo

引用次数: 0

Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. 原发性血小板增多症和真性红细胞增多症低危患者的管理问题和争议。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-09-03 DOI: 10.1007/s11899-021-00649-x

Joan How, Gabriela Hobbs

{"title":"Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera.","authors":"Joan How, Gabriela Hobbs","doi":"10.1007/s11899-021-00649-x","DOIUrl":"https://doi.org/10.1007/s11899-021-00649-x","url":null,"abstract":"Purpose of review: Essential thrombocythemia (ET) and polycythemia vera (PV) are the most common myeloproliferative neoplasms (MPNs). Treatment of ET and PV is based on the risk for subsequent thrombosis. High-risk patients, defined as older than 60, JAK2 V617F-positive patients, or patients with a history of prior thrombosis, merit cytoreduction to control blood counts, whereas a watchful waiting paradigm is utilized in low-risk patients. However, low-risk patients have a host of other specific management issues that arise during their disease course. This review will discuss the most common management issues specific to the care of low-risk patients, including anti-platelet therapy dosing, pregnancy, and indications for early cytoreduction.Recent findings: Although low-dose aspirin is well established in PV, its indications and dosing regimens are less clear in ET. Recent evidence has supported twice daily low-dose aspirin in ET and observation alone in very low-risk ET patients. Pregnancy is not contraindicated in MPNs, and we recommend aspirin throughout pregnancy with consideration for prophylactic postpartum anticoagulation. High phlebotomy needs, symptom burden, and extreme thrombocytosis are common reasons for initiation of cytoreduction in low-risk patients, although we typically do not start cytoreduction for an isolated high platelet count alone. Recent data has also demonstrated a potential disease-modifying effect of interferons in MPNs, with some experts now advocating the early use of interferon in low-risk patients, although more mature data is needed before practice guidelines change. We evaluate the literature to inform clinical decision-making regarding these controversies, including most recent data that has challenged the \"watchful waiting\" paradigm. Our discussion provides guidance on common clinical scenarios seen in low-risk ET and PV patients, who face a myriad of complex management decisions in their care.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"473-482"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39383536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials. 骨髓纤维化相关性贫血的治疗:在3期临床试验中关注标准药物和新疗法。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-09-09 DOI: 10.1007/s11899-021-00651-3

Brady L Stein

{"title":"Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials.","authors":"Brady L Stein","doi":"10.1007/s11899-021-00651-3","DOIUrl":"https://doi.org/10.1007/s11899-021-00651-3","url":null,"abstract":"Purpose of review: The management of myelofibrosis is risk-adapted when considering transplant eligibility and symptom-directed, prioritizing the most burdensome symptoms for the patient. Unfortunately, myelofibrosis-anemia is common, multifactorial in its origin, and impactful regarding prognosis. While clinical trials are advised, not all patients have convenient access, and therefore, hematologists should be aware of the data supporting the use of conventional agents such as erythropoietin-stimulating agents, steroid treatments (danazol and prednisone), and immunomodulatory drugs (thalidomide and lenalidomide). This review summarizes the conventional approach to treating myelofibrosis-anemia and highlights recent data from 3 novel agents that are under phase 3 evaluation.Recent findings: Momelotonib is a JAK1/2 and ACVR1 inhibitor that has demonstrated not only improvements in splenomegaly and symptoms, but also amelioration of anemia on the SIMPLIFY 1 and 2 clinical trial program. This may occur through suppression of hepcidin production. Luspatercept promotes late-stage hematopoiesis, and the phase 2 study has shown promise in ameliorating anemia as a monotherapy, and especially in combination with ruxolitinib. Finally, CP-0160, a BET inhibitor, has shown efficacy as an anemia-directed agent, when used as monotherapy and in combination. This agent reduces cytokine production and promotes erythroid differentiation. Results have been presented for patients previously treated with JAK inhibitors, as well as those who were naïve to JAK inhibitor therapy. Safety and effectiveness are reviewed for both conventional and selected novel agents used in the treatment of MF-anemia. A practical approach to treatment is presented, and data from ASH 2020 are presented.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"483-489"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39398868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic. 围绕 COVID-19 大流行的费城阴性骨髓增生性肿瘤。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-09-29 DOI: 10.1007/s11899-021-00647-z

Tiziano Barbui, Valerio De Stefano

{"title":"Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.","authors":"Tiziano Barbui, Valerio De Stefano","doi":"10.1007/s11899-021-00647-z","DOIUrl":"10.1007/s11899-021-00647-z","url":null,"abstract":"Purpose of review: Coronavirus disease 2019 (COVID-19) is associated with a high rate of respiratory failure, thromboembolism, bleeding, and death. Patients with myeloproliferative neoplasms (MPNs) are prone to both thrombosis and bleeding, calling for special care during COVID-19. We reviewed the clinical features of MPN patients with COVID-19, suggesting guidance for treatment.Recent findings: One study by the European LeukemiaNet collected 175 MPN patients with COVID-19 during the first wave of the pandemic, from February to May 2020. Patients with primary myelofibrosis (PMF) were at higher risk of mortality (48%) in comparison with essential thrombocythemia (ET) (25%) and polycythemia vera (19%); the risk of death was higher in those patients who abruptly discontinued ruxolitinib. In patients followed at home, in regular wards, or in ICU, the thrombosis rate was 1.0%, 2.8%, and 18.4%, respectively. Independent risk factors for thrombosis were ET phenotype, transfer to ICU, and neutrophil/lymphocyte ratio; major bleeding occurred in 4.3% of patients, particularly those with PMF. MPN patients with non-severe COVID-19 treated at home should continue their primary or secondary antithrombotic prophylaxis with aspirin or oral anticoagulants. In the case of hospitalization, patients assuming aspirin should add low molecular weight heparin (LMWH) at standard doses. In contrast, LMWH at intermediate/therapeutic doses should replace oral anticoagulants prescribed for atrial fibrillation or previous venous thromboembolism. Intermediate/high doses of LMWH can also be considered in ICU patients with ET, particularly in the case of a rapid decline in the number of platelets and progressive respiratory failure.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"455-463"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39491927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML). 慢性期慢性髓性白血病(CML)一线治疗的发展前景。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-10-18 DOI: 10.1007/s11899-021-00655-z

Heather R Wolfe, Lindsay A M Rein

{"title":"The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML).","authors":"Heather R Wolfe, Lindsay A M Rein","doi":"10.1007/s11899-021-00655-z","DOIUrl":"https://doi.org/10.1007/s11899-021-00655-z","url":null,"abstract":"Purpose of review: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by uncontrolled proliferation of mature and maturing granulocytes. The disease is characterized by the presence of translocation t(9;22) leading to the abnormal BCR-ABL fusion. Historically, treatment options included hydroxyurea, busulfan, and interferon-α (IFN-α), with allogeneic stem cell transplant being the only potential curative therapy. More recently, the development of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML and turned a once fatal disease into a chronic and manageable disorder. This review aims to discuss the frontline treatment options in chronic-phase CML, provide recommendations for tailoring frontline treatment to the patient, and explore emerging therapies in the field.Recent findings: The first-generation TKI, imatinib, was FDA approved in 2001 for use in CML. Following the approval and success of imatinib, second- and third-generation TKIs have been developed providing deeper responses, faster responses, and different toxicity profiles. With numerous options available in the frontline setting, choosing the best initial treatment for each individual patient has become a more complex decision. When choosing a frontline therapy for patients with chronic-phase CML, one should consider disease risk, comorbid conditions, and the goal of therapy.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"448-454"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39529393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Targeting BCMA in Multiple Myeloma. 靶向BCMA治疗多发性骨髓瘤

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-08-25 DOI: 10.1007/s11899-021-00639-z

Carlyn Rose Tan, Urvi A Shah

{"title":"Targeting BCMA in Multiple Myeloma.","authors":"Carlyn Rose Tan, Urvi A Shah","doi":"10.1007/s11899-021-00639-z","DOIUrl":"https://doi.org/10.1007/s11899-021-00639-z","url":null,"abstract":"Purpose of review: Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies. Here, we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antibody receptor (CAR) modified T-cell therapies. We will provide an overview of therapies from these classes that have presented or published clinical data, as well as data on mechanisms of resistance to these novel agents.Recent findings: Clinical trials exploring different BCMA-targeting modalities to treat multiple myeloma are underway and demonstrate promising results. In relapsed/refractory multiple myeloma, anti-BCMA ADCs and bispecific antibody constructs are showing impressive efficacy with manageable side effect profiles. In parallel, adoptive cellular therapy has induced dramatic durable responses in multiply relapsed and refractory myeloma patients. Therapeutic approaches targeting BCMA hold significant potential in the management of multiple myeloma and will soon be incorporated in combination with current standard therapies to improve outcomes for patients with multiple myeloma. In addition, novel approaches are being evaluated to overcome resistance mechanisms to anti-BCMA therapies.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"367-383"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11899-021-00639-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39343032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Treatment-Free Remission: the New Goal in CML Therapy. 无治疗缓解:慢性粒细胞白血病治疗的新目标。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-10-07 DOI: 10.1007/s11899-021-00653-1

Ehab Atallah, Kendra Sweet

{"title":"Treatment-Free Remission: the New Goal in CML Therapy.","authors":"Ehab Atallah, Kendra Sweet","doi":"10.1007/s11899-021-00653-1","DOIUrl":"https://doi.org/10.1007/s11899-021-00653-1","url":null,"abstract":"Purpose of review: Treatment-free remission (TFR) is considered one of the main goals of therapy in patients with CML. Our goal in this paper is to review the current data on TFR, and discuss future directions.Recent findings: Multiple studies have demonstrated that attempting a treatment-free remission is safe and effective in a select group of patients. More recent data suggested that undetectable BCR-ABL1 by digital PCR prior to discontinuation is highly predictive of successful TFR. However, some patients have a successful TFR with no evidence of clinical disease despite persistent detectable BCR-ABL1. Some recent studies have shed some more light on possible mechanisms for this phenomena. Some possible mechanisms include immune mechanism, BCR-ABL1 detected in the lymphoid component only, or stem cell exhaustion. TFR should be discussed with patients with CML. Patients who achieve a sustained deep molecular response may be eligible to attempt TFR, however, setting expectations that overall only 20% of patients with newly diagnosed CML will achieve a successful TFR. The importance of compliance to treatment early on cannot be overemphasized. Further studies using other drugs to get patients to a deeper remission in order to be eligible for TFR attempt, or attempting a second TFR in patients who had disease recurrence after first TFR attempt, are currently underway.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"433-439"},"PeriodicalIF":2.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39496103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14